綠葉製藥(02186.HK)擬發行12億人幣可轉換債券
綠葉製藥(02186.HK)公布,擬向獨立第三方「新葉生物醫藥控股」發行12億元人民幣等額的公司債券,另授出增發期權,可於30個營業日內認購本金額為3億元人民幣等額港元的增發債券。
有關債券年利率6.5厘,可轉換為股份,初步換股價3.5元,較昨日(27日)收市價2.43元溢價44.03%。公司債券可轉換為3.98億股,佔公司擴大後股本10.08%,料淨集資約13.71億元;如連同增發債券計算則可共轉換為4.97億股,佔公司擴大後股本12.29%,料淨集資17.14億元。所得款項淨額擬用作一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.